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Abstract
Background: In 2009 a new pandemic disease appeared and spread globally. The recent emergence of the pandemic
influenza virus H1N1 first isolated in Mexico and USA raised concerns about vaccine availability. We here report our
development of an adenovirus-based influenza H1N1 vaccine tested for immunogenicity and efficacy to confer protection
in animal model.
Methods: We generated two adenovirus(Ad5)-based influenza vaccine candidates encoding the wildtype or a codon-
optimized hemagglutinin antigen (HA) from the recently emerged swine influenza isolate A/California/04/2009 (H1N1)pdm.
After verification of antigen expression, immunogenicity of the vaccine candidates were tested in a mouse model using
dose escalations for subcutaneous immunization. Sera of immunized animals were tested in microneutalization and
hemagglutination inhibition assays for the presence of HA-specific antibodies. HA-specific T-cells were measured in IFNc
Elispot assays. The efficiency of the influenza vaccine candidates were evaluated in a challenge model by measuring viral
titer in lung and nasal turbinate 3 days after inoculation of a homologous H1N1 virus.
Conclusions/Significance: A single immunization resulted in robust cellular and humoral immune response. Remarkably,
the intensity of the immune response was substantially enhanced with codon-optimized antigen, indicating the benefit of
manipulating the genetic code of HA antigens in the context of recombinant influenza vaccine design. These results
highlight the value of advanced technologies in vaccine development and deployment in response to infections with
pandemic potential. Our study emphasizes the potential of an adenoviral-based influenza vaccine platform with the
benefits of speed of manufacture and efficacy of a single dose immunization.
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Introduction
Events of the past six months have brought home to the world
that a new pandemic disease has appeared in our midst. The
pandemic caused by a swine-origin influenza virus A H1N1 and
first isolated from humans in Mexico and the USA has spread
globally [1–3]. As of December 30
th, over 12.220 deaths have been
reported associated with this outbreak (http://www.who.int/csr/
don/2009_12_30/en/index.html). Through the efforts of an
international consortium of laboratories, the swine-origin influen-
za virus H1N1 was identified in less than 2 months following its
first appearance in Mexico and the antigenic and genetic
characteristics of 71 isolates have been investigated [4;5].
Phylogenetic analysis enabled the identification of the newly
emerged swine-origin influenza virus A H1N1 as a reassortant
virus evolved from a classical swine H1N1 lineage, an avian-like
Eurasian swine H1N1 lineage and from the North America H3N2
triple reassortant influenza lineage [6;7]. To prevent and control
this unique pandemic swine-origin influenza virus H1N1, both
vaccine and antiviral drugs are now available. Antiviral drugs of
the neuraminidase inhibitor group have been used effectively
against influenza viruses but might not be in sufficient supply and
the virus may acquire resistance to the available antiviral
drugs [8]. A monovalent influenza virus vaccine has been rapidly
produced by standard techniques and is being evaluated in clinical
trials [9]. However, it appears that the production of large
amounts of egg-produced swine influenza H1N1 vaccine has
limited capability due to suboptimal yields (http://www.npr.
org/blogs/health/2009/07/manufacturing_problems_with_sw.html).
This could severely hinder the ability to produce large amount of
vaccines in a timely manner for efficient control of pandemic spread
via vaccination.
As human infection with H1N1 viruses continue to increase, so
too does the likelihood of antigenic drift and shift leading to
generation of novel viruses with potential for higher morbidity and
mortality rates and hindering the efficacy of current vaccines.
Alternative or complementary vaccine strategies with the feature
of speed for manufacture and high yields of vaccine production as
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beneficial.
Recombinant DNA vaccines are highly effective inducers of
both humoral and cellular immunity and show promise in the
prevention of human disease in animal models [10–13]. The
successful use of recombinant adenoviruses encoding hemagglu-
tinin from highly pathogenic influenza viruses with pandemic
potential has been previously demonstrated [14;15]. In this study
we tested two adenovirus-based influenza vaccine candidates in an
animal model to induce effective H1N1 swine influenza specific
immune responses combined with protection.
Results
We generated E1/E3-deleted adenoviral (Ad5)-based vectors
encoding the wildtype (AdHA.wt) or a codon-optimized (AdHA.cod)
hemagglutinin (HA) gene from A/California/04/2009 (H1N1)pdm
influenza virus. Codon-optimization using the UpGene algorithm
improves expression levels of the antigen in infected mammalian
cells and consequently enhances immune responses against the
antigen in vivo[16]. The generation of the recombinant adenoviral
vectors was completed 14 days (AdHA.wt) and 21 days (AdHA.cod)
after acquisition of the A/California/04/2009 (H1N1)pdm HA
sequence, illustrating the rapid construction and ease of manipula-
tion necessary for adenovirus-based vaccine development.
Initially, the recombinant adenoviral vaccines were evaluated in
A549 cells where HA antigen expression levels after infection were
examined by immunoblot (Fig. 1A) and flow cytometry (Fig. 1B)
analysis using ferret and mouse antiserum. Notably, poor HA
expression was seen in cells infected with AdHA.wt, whereas stronger
HA expression was detected after infection with AdHA.cod.
To compare the ability of the two AdHA vaccine candidates to
induce HA-specific immune responses, eleven groups of Balb/c
mice were immunized subcutaneously with increasing doses of
AdHA.wt, AdHA.cod or with Ad5 control. Four weeks after
immunization serum samples were obtained from all mice to screen
for H1N1 specific antibodies in hemagglutination inhibition (HI)
assay using the influenza strain A/Texas/05/09 (H1N1)pdm as
source of homologous antigen. HA-specific antibodies response was
detected in the animals immunized with AdHA.wt and AdHA.cod.
Remarkably, AdHA.cod immunization required at least three log10
less vaccine to achieve the same level of HI immunity measured in
the AdHA.wt groups (Fig. 2A). Given that vaccination with
AdHA.cod and AdHA.wt induced various degrees of humoral
immunity we then only used the highest vaccine dose (5610
10 vp/
mouse) for immunization for further characterization of the
AdHA.wt, AdHA.cod vaccine candidates. To determine the degree
to which antibody responses could neutralize homologous A/
Texas/05/09 (H1N1)pdm influenza virus, indicating the potential
of protection, sera were tested inmicroneutralization assay(Fig.2B).
Neutralization titers, measured at week 5 after immunization, of
$640 were observed in AdHA.cod and in some AdHA.wt
immunized animals, again with a significant increase in geometric
means of neutralization titers observed after AdHA.cod immuniza-
tion. To determine T-cell specific responses to HA by immunized
mice, ELISPOT assays measuring IFN-c secretion were performed
on splenocytes collected at week 5 post vaccination using a
previously described heterosubtypic conserved peptide encoded in
the HA2 portion of HA antigen [14] as the target T-cell epitope.
Both vaccine candidates, AdHA.wt and AdHA.cod, were able to
induce HA-peptide-specific T-cell responses (Fig. 2C). However, as
seen with antibody responses, the AdHA.cod vaccine induced a
greater T-cell specific response.
To investigate the protective efficacy of these AdHA vaccine
candidates against challenge with the H1N1 virus we utilized a
mouse model [17]. Animals were intranasally inoculated with
1000 PFU A/Ohio/7/09 (H1N1)pdm 5 to 6 weeks after the
single dose immunization. Three days post-challenge, the mice
were sacrificed, their lungs and nasal turbinate harvested and
viral titers were determined by plaque formation assay performed
in MDCK-L cells. As expected, the mock-immunized group had
positive H1N1 titer in lung and nasal turbinate. No measurable
Figure 1. Verification of gene expression by the H1N1 vaccine candidates. HA expression in A549 cells transduced with AdHA.wt, AdHA.cod
or Ad5. A, HA detection in cell lysates by western blot analysis (60 ug of total protein loaded in each lane) using ferret antiserum. B, Flow cytometric
analysis of HA expression at the cell surface using ferret or mouse antiserum. Shown are the percentages of HA positive cells.
doi:10.1371/journal.pone.0010492.g001
Adenovirus-Based H1N1 Vaccine
PLoS ONE | www.plosone.org 2 May 2010 | Volume 5 | Issue 5 | e10492Figure 2. Induction of humoral and cellular immune responses by the H1N1 vaccine candidates. Induction of influenza H1N1-specific
immune responses after subcutaneous immunization of Balb/c mice with adenovirus encoding wildtype (AdHA.wt) or codon-optimized (AdHA.cod)
HA antigen or control adenovirus (Ad5). A, Antibody to influenza A/Texas/05/09 (H1N1)pdm in sera of mice after receiving dose escalations of the
vaccine candidates (AdHA.wt or AdHA.cod). Shown are log2 values of HI-titer. Horizontal lines represent geometric means in each group. B, Induction
Adenovirus-Based H1N1 Vaccine
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10492virus titers were detected in lung and nasal turbinate in the
AdHA.cod immunized group (Fig. 3). Somewhat lower levels of
protection were observed in the AdHA.wt immunized group. As
shown in table 1, in AdHA.wt immunized group 2 out of 10
animals had positive H1N1 titer revealing a correlation between
the magnitude of the immune response and protection from
H1N1 challenge.
Discussion
This study demonstrates that a single-dose of codon-optimized
adenovirus-based H1N1 vaccine expressing HA derived from
influenza virus A/California/04/2009 (H1N1)pdm efficiently
induces HA-specific antibodies and T-cells in mice that correlates
with protection when measured as the elimination of detectable
virus titers in lungs and nasal turbinates 3 days after challenge.
The intensity of the immune response was greater in the group of
mice immunized with AdHA.cod, indicating a benefit associated
with optimizing the genetic code of antigen-expressing genes in
recombinant vaccines as observed in other studies [18–20].
Though the correlation of induction of HA-specific antibodies to
vaccine doses was clearly demonstrated, we did not measure T-cell
frequencies following immunization with different vaccine doses.
Thus, future studies to determine the impact of T cell frequency
and the correlation with HA antigen expression levels and
protection would be of great interest.
These findings can be extended to other genetically engineered
H1N1 influenza vaccines using reverse genetic techniques [21;22]
or using other recombinant viral vectors [23–25], and warrant the
use of a codon-optimized version of the gene encoding HA.
Enhancing the HA expression in the reassortant influenza vaccine
strain could result in higher yields of the HA protein purified from
the allantoic fluid of virus infected chicken eggs and consequently
more vaccine doses per batch.
The use of recombinant adenoviral vectors to immunize against
infectious diseases and cancer has been proven safe in more than
100 phase I, II, and III clinical trials. The effective use of
adenoviral-based influenza HA vaccines was demonstrated in
previous studies in mice, chickens and humans [14;15;26] showing
promising results indicating the adenoviral platform as a safe and
practicable alternative to propagating vaccines with conventional
methods in embryonated chicken eggs. Moreover, the ability to
produce the adenoviral seed stock generation only 2–3 weeks after
the appearance of the newly emerged influenza strain is one of the
most valuable properties of this vaccine technology. However,
natural pre-existing immunity against adenoviral vectors [27]
could potentially reduce vaccine efficacy. While the impact of
natural neutralizing antibodies on the induction of effective
immune responses is still controversial, the effective delivery of
an adenovirus-based influenza HA vaccine via the mucosal route
has been demonstrated, by van Kampen et al and our own results
(data not shown), effective despite the presence of anti-adenoviral
antibodies, suggesting that vector-specific immunity may be
overcome [26]. Extensive in vivo work comparing different routes
of administration as a way to overcome pre-existing adenoviral
neutralizing immunity is underway in our laboratory and will be
the subject of future manuscripts.
Alternatively, a wide range of different human and animal
adenovirus serotypes, as well as structural and nonstructural
modifications of adenoviral vectors, have been investigated to
circumvent pre-existing adenoviral immunity [28–31].
In conclusion, this study further emphasizes the vaccine
potential of an adenoviral-based platform with the advantages of
speed for the seed stock generation and high yields of vaccine virus
in a large-scale production. Furthermore, this vaccine elicits robust
cellular and humoral immunity after a single dose immunization.
These properties are invaluable when rapid vaccine development
and production are required to control the virus spread and
mitigate the public health impact of pandemic influenza. Although
still experimental, these results mandate further testing of
adenovirus-based influenza vaccine technology in human clinical
trials.
Figure 3. Induced protection against H1N1 by the H1N1 vaccine candidates. Protection of immunized animals (5 or 6 weeks after
immunization with AdHA.wt vs Ad5 control or AdHA.cod vs Ad5 control) against an intranasal challenge with 1000 pfu of A/Ohio/7/09 (H1N1)pdm
was measured as viral titers in lung and nasal turbinate determined 3 days post-inoculation in a plaque formation assay using MDCK-L cells. Shown
are log10 values of mean titer for each group 6 SEM. The horizontal dashed line represents the lower limit of detection of the assay.
doi:10.1371/journal.pone.0010492.g003
of H1N1-specific neutralizing antibodies in sera 5 weeks after immunization with AdHA.wt, AdHA.cod or Ad5 control. Shown are neutralizing antibody
titer to influenza A/Texas/05/09 (H1N1)pdm measured by microneutralization assay. Horizontal lines represent geometric means in each group. C, HA
peptide specific T cell responses in splenocytes detected in IFNc Elispot assays. A representative result is shown as means of SFC 6 SEM of triplicate
determinations in each group.
doi:10.1371/journal.pone.0010492.g002
Adenovirus-Based H1N1 Vaccine
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Ethics Statement
All animals were housed and handled according to the
University of Pittsburgh’s Institutional Animal Care and Use
Committee guidelines and all animal work was approved by the
appropriate committee (IACUC 0909547 and 0802046A-1).
Viruses and Cells
A549, a human lung adenocarcinoma epithelial cell line, cells
were obtained from ATCC. A/California/04/2009, A/Texas/05/
09, A/Ohio/7/09 pandemic H1N1, (H1N1)pdm, influenza viruses
were obtained from the Influenza Reagent Resource or the WHO
Influenza Collaborating Center in Atlanta. The three viruses are
antigenically identical to A/California/07/2009 (H1N1)pdm,
which was recommended for vaccine development by the WHO.
Different pandemic virus strains were used in HI, microneutraliza-
tion and challenge assays according to their availability.
Gene synthesis and adenoviral vector constructions
Hemagglutinin HA gene (GenBank Accession FJ966082) was
PCR amplified from influenza virus A/California/04/2009
followed by cloning into pCI vector. Alternatively the HA gene
was codon-optimized for optimal expression in mammalian cells
by the UpGene codon optimization algorithm (http://www.
vectorcore.pitt.edu/upgene.html) and synthesized by GenScript.
Both genes were subcloned into pAdlox (GenBank U62024) to
generate recombinant adenoviruses of the serotype 5 as previously
described [14;32]. Generation of the wild type HA-encoding
adenovirus (AdHA.wt) required 14 days. Conversely the genera-
tion of the codon-optimized HA-encoding adenovirus, due to the
extra time required for the gene synthesis, required 21 days. All
vaccine candidates were controlled by sequencing.
HA expression analysis
A549 cells were seeded at 6-well plates and infected with
AdHA.wt, AdHA.cod or Ad5 (10
10 vp/well). After 24 h at 37uC,
cells were harvested, trypsinized, washed with PBS and stained with
ferret antiserum against A/Texas/05/09 (H1N1)pdm or mouse
antiserum against AdHAcod followed by a FITC-conjugated anti-
ferret or PE-conjugated anti-mouse secondary antibody. Data
acquisition and analysis was performed using a FACScan and
CELLQuest software. Alternatively, cell lysates of AdHA-infected
A549 cells were tested for HA expression in western blot analysis
using ferret antiserum (against A/Texas/05/09 (H1N1)pdm).
Animal studies
Female Balb/c mice (five mice per group) were immunized via
subcutaneous inoculation of 5610
10,5 610
9,5 610
8,5 610
7 or
5610
6 virus particles each of AdHA.wt, AdHA.cod and 5610
10
control Ad5 virus. Four weeks later immune sera and splenocytes
were harvested and further tested in HI assay and IFNc Elispot.
For challenge studies ten mice per group were immunized via
subcutaneous inoculation of 5610
10 virus particles each of
AdHA.wt or control Ad5 virus. Due to delayed availability of
the codon-optimized gene, groups of animals received 5610
10 vp
of AdHA.cod vaccine or control Ad5 one week later. All groups
were intranasally challenged at the same time with a non-lethal
dose (1000 PFU) of influenza A/Ohio/7/09 (H1N1)pdm in 50 ml
of PBS. At 3 days after inoculation lungs and nasal turbinates were
collected for virus quantification.
Hemagglutination inhibition test
Four weeks after immunization, sera were collected and treated
with receptor destroying enzyme (RDE) (Denka-Seiken) and
subsequently tested in a standard hemagglutination inhibition test
using 4 HAU of influenza A/Texas/05/09 (H1N1)pdm virus as
source of antigen and 0.5% turkey red blood cell solution in PBS
[14].
Microneutralization assay
Serum neutralizing antibody titers were determined by
seeding MDCK cells at 1.5610
4 cells/well in 96-well culture
plates and culturing at 37uCi n5 %C O 2 to form a monolayer.
Serial two fold dilutions of heat inactivated serum samples were
mixed separately with 100 TCID50 of A/Texas/05/09
(H1N1)pdm and incubated at room temperature for 2 h. The
mixture was added to monolayer of MDCK cells in triplicate
wells. The plates were incubated for 18 h at 37uCa n d5 %
CO2.The monolayers were washed with PBS and fixed in cold
80% acetone for 10 min. The presence of viral protein was
detected by ELISA with a monoclonal antibody to the influenza
A NP and endpoint titer were determined as described
previously [33].
ELISPOT assay for IFNc
96-well Elispot plates (MAHA S4510, Millipore) were incubated
with 10 ug/ml of monoclonal antibody to mouse IFNc (clo-
neR46A2, eBioscience) in PBS. Splenocytes were plated at 10
6
cells per well in medium containing 10% FBS and stimulated with
10 ug/ml of the previously described HA2 peptide IYQILSIYST-
VASSL [14]. This hetrosubtypic peptide was used due to
availability and homology to the HA2 peptide encoded by
H1N1 IYQILAIYSTVASSL. After incubation at 37uC for 24 h,
wells were washed and incubated with biotinylated antibody to
mouse IFN-c (clone XMG 1.2, eBioscience) overnight at at 4uC.
After washing with tap water and 1 h incubation with streptavidin-
AP conjugate (Dako) at room temperature spots were developed
using alkaline phosphatase substrate BCIP/NBT (Sigma) and
enumerated using a dissecting microscope.
Viral lung titer measurement
Three days post infection with influenza virus A/Ohio/7/
09(H1N1), mice were sacrificed and lungs and nasal turbinates
were collected and frozen at 280uC. Tissue homogenates were
prepared by mechanical disruption and used to determine viral
titers by plaque formation assay performed in MDCK-L cells in
the presence of trypsin [34].
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